AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech宣布在Ampligen和Imfinzi作为晚期胰腺癌联合疗法的1B/2期研究中,首剂量水平总体上耐受性良好
AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech宣布在Ampligen和Imfinzi作为晚期胰腺癌联合疗法的1B/2期研究中,首剂量水平总体上耐受性良好
使用浏览器的分享功能,分享给你的好友吧